The Cooper Companies, Inc.
COOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeThe Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. Valued at $11.74B, COO is a large-cap name in its sector. The company operates in two segments, CooperVision and CooperSurgical.
Market Cap
$11.74B
Beta
0.89
P/E (TTM)
29.95
P/E (Fwd)
12.00
EPS (TTM)
$2.01
EPS (Fwd)
$5.01
ROE
4.9%
ROA
3.6%
Cash
$124.9M
Total Debt
$2.78B
Free CF
$367.1M
52W Change
-10.0%
Annual Financials
Cash vs Debt
The Cooper Companies, Inc. carries $2.78B in total debt against $124.9M in cash reserves — debt is roughly 22.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $367.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 4.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.31B (2022) to $4.09B (2025), reflecting a 24% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing COO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.